PSIL stock forecast, quote, news & analysis

The most notable companies in this group are Intra-Cellular Therapies (NASDAQ:ITCI).

The investment seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.

The average market capitalization across the AdvisorShares Psychedelics ETF ETF is 890.02M. The market cap for tickers in the group ranges from 313.8K to 6.7B. ITCI holds the highest valuation in this group at 6.7B. The lowest valued company is SEEL at 313.8K.

The average weekly price growth across all stocks in the AdvisorShares Psychedelics ETF ETF was -5%. For the same ETF, the average monthly price growth was -9%, and the average quarterly price growth was 5%. ATAI experienced the highest price growth at 14%, while PBM experienced the biggest fall at -34%.

The average weekly volume growth across all stocks in the AdvisorShares Psychedelics ETF ETF was 28%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was 233%